Hepatocellular Carcinoma Drugs Market: Rise in Mortality Associated with Liver Cancer Across the Globe to Drive the Market

Hepatocellular Carcinoma Drugs Market: Introduction

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, accounting for 75% to 80% of liver cancers worldwide. It is one of the leading causes of cancer-related deaths across the globe. Incidence of chronic liver disease is rising owing to the higher incidence of hepatitis B and hepatitis C. The prevalence of HCC is more in Asia and Africa, as compared to North America and Europe. The incidence of HCC is highest in Asia, with incidence rates in men of 35 per 100,000 populations.

Read Report Overview - https://www.transparencymarketresearch.com/hepatocellular-carcinoma-drugs-market.html

Excessive alcohol consumption leading to liver cirrhosis, viral infections such as hepatitis B and C, and lifestyle disorders are some of the major risk factors associated with the development of hepatocellular carcinoma. Hepatocellular carcinoma drugs are used to treat such life-threatening disorders. Sorafenib, nivolumab, regorafenib, lenvatinib, cabozantinib, and pembrolizumab are the latest available drugs for patients with advanced HCC.

Key Drivers, Restraints, and Opportunities of Global Hepatocellular Carcinoma Drugs Market

Increase in the incidence of hepatocellular carcinoma and rise in mortality associated with liver cancer across the globe are major factors driving the hepatocellular carcinoma drugs market. According to the American Cancer Society, nearly 42,030 new patients are likely to be diagnosed with liver cancer in the U.S. in 2019. Of these, three-fourths would be accountable for HCC.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=59028

Similarly, approximately 31,780 liver cancer deaths are estimated to have occurred in the U.S. in 2019. Changing lifestyles, obesity, high blood pressure, diabetes, and increase in geriatric patient population are other factors that are anticipated to boost the global hepatocellular carcinoma drugs market during the forecast period.

Increase in the number of clinical trials for hepatocellular carcinoma drugs by major industry players is expected to create significant opportunities in the market from 2021 to 2031. For instance, Bayer AG, Bristol Myers Squibb, Eisai, Merck Co., & Inc., Eli Lilly, and Novartis AG are a few industry players with a strong pipeline of drugs for hepatocellular carcinoma. However, side-effects of hepatocellular carcinoma drugs and stringent regulatory scenario are expected to restrain the hepatocellular carcinoma drugs market in the next few years.

North America to Capture Major Share of Global Hepatocellular Carcinoma Drugs Market

The global hepatocellular carcinoma drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to account for dominant share of the global market between 2021 and 2031. This is attributed to a rise in the prevalence of hepatocellular carcinoma, increase in the number of deaths associated with the disease in the U.S., and increase in the number of clinical trials undertaken by manufacturers in the country. The market in Europe is anticipated to expand at a substantial growth rate during the forecast period. Increase in the prevalence of hepatitis B and hepatitis C leading to the development of HCC in emerging countries, such as India and China, is a major factor boosting the hepatocellular carcinoma drugs market in Asia Pacific.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=59028

Moreover, a rise in the baby boomer population and increase in prevalence of lifestyle diseases such as obesity and diabetes increase the risk of hepatocellular carcinoma. This is expected to drive the demand for hepatocellular carcinoma drugs in the region. High incidence of viral hepatitis leading to chronic liver disease in Africa is anticipated to propel the hepatocellular carcinoma drugs market in Middle East & Africa.

Key Players Operating in Global Hepatocellular Carcinoma Drugs Market

Key players operating in the global hepatocellular carcinoma drugs market are Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Co. Ltd., Johnson & Johnson, Exelixis, Eisai, Merck & Co., Inc., Pfizer Inc., GlaxoSmith Kline, Celgene Corporation, Teva Pharmaceutical Industries Ltd. and Amgen, among others. Market players focus on investments in R&D to develop novel drugs for the effective treatment of hepatocellular carcinoma in order to expand their product portfolio and strengthen their geographical reach.

Pre Book Hepatocellular Carcinoma Drugs Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=59028&ltype=S

Major Players operating in the global hepatocellular carcinoma drugs market are:

  • Bayer AG
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical Co. Ltd.
  • Johnson & Johnson, Exelixis
  • Eisai
  • Merck & Co., Inc.
  • Pfizer Inc.
  • GlaxoSmith Kline
  • Celgene Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Amgen
  • Exelixis, Inc.
  • Merck & Co., Inc.
  • AstraZeneca
  • Eli Lilly and Company
  • SillaJen, Inc.
  • Janssen Global Services, LLC
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • Transgene
  • Takeda Pharmaceutical Company Limited,
  • Polaris Pharmaceuticals
  • Hepion Pharmaceuticals

Browse More Trending Reports by Transparency Market Research:

Blood Culture Tests Market: https://www.transparencymarketresearch.com/blood-culture-tests-market.html

3D Cell Culture Market: https://www.transparencymarketresearch.com/3d-cell-culture-market.html

Anti-parasitic Drugs Market: https://www.transparencymarketresearch.com/antiparasitic-drugs-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/

Back to news